Objective: Deep brain stimulation (DBS) alleviates the cardinal Parkinson disease (PD) symptoms of tremor, rigidity, and bradykinesia. However, its effects on postural instability and gait disability (PIGD) are uncertain. Contradictory findings may be due to differences the in stimulation site and the length of time since DBS surgery. This prompted us to conduct the first meta-regression of long-term studies of bilateral DBS in the subthalamic nucleus (STN) and globus pallidus interna (GPi).
STN and GPi project to different motor pathways within the CNS, stimulation at these sites may contribute differently to axial control.
The choice of target for DBS is dependent on the experience and judgment of the neurologist and neurosurgeon. STN DBS has more of a proven record than GPi stimulation, although the choice of STN is questioned in patients with cognitive or speech impairment. [11] [12] [13] However, in cases where a reduction in dopaminergic medication has been the postsurgical goal, due to medication intolerance or compulsive behaviors, STN has remained the target of choice. The relative effects of DBS in the STN and GPi on postural stability and gait are unclear because experimental studies almost always report only one or the other DBS target.
A meta-analysis by Bakker and colleagues 14 of the effects of DBS on the international gold standard clinical assessment for PD, the UPDRS, suggests that PIGD is improved by DBS in both the STN and GPi when tested within a year after surgery. The metaregression of the current study follows the progression of both PD cardinal and PIGD symptoms over several years to better understand the relative long-term effects of DBS on bradykinesia, tremor, and rigidity vs posture and gait. If improvement in PIGD changes differently over time than the cardinal signs, this is consistent with differential effects of DBS on the distal and axial neural control circuits. Additionally, if the long-term progression of DBS in STN and GPi on PIGD differ, this could influence the target for patients with PD who have significant balance and gait problems. The study complied with the Meta-analysis of Observational Studies in Epidemiology guidelines. 15 METHODS Search strategy and selection criteria. References were identified by search of PubMed, Medline, and Scopus electronic databases published before July 2009 with the terms "PD" and "deep brain stimulation," or "subthalamic nucleus stimulation," or "globus pallidus stimulation." Articles were also identified through examination of the reference lists of relevant publications and a search of the authors' own reference database. Articles were selected for inclusion only if they provided UPDRS ratings before surgery and follow-up ratings with a final assessment a minimum of 3 years after surgery. Statistical variance, the number of subjects at each assessment period, levodopa-equivalent daily dosage, and stimulation settings were also required.
Thirteen observational studies fulfilled the selection criteria. Two of these studies were excluded 16, 17 because the population samples were subsets of the populations in 2 other articles that were included because they had larger sample sizes. 18, 19 Of the remaining 11 studies, 3 examined bilateral GPi, 9 examined bilateral STN stimulation, and 1 study included both STN and GPi target sites. 19 In the Lyons et al. 20 study, 3 of the 9 subjects had unilateral GPi stimulation but the results lumped the unilateral and bilateral cases. As there were so few studies of the GPi, this study was included but the reported effects may be underestimated for this reason.
In all studies, the UPDRS was assessed by a neurologist specializing in movement disorders and patients with cognitive impairment were excluded. Subjects were evaluated in the mornings in the "practically off " state a minimum of 8 hours after withdrawal of antiparkinsonian medication, with most studies waiting at least 12 hours. The "best on" state was assessed within 90 minutes of administration of a dose of levodopa. In 4 studies, this was a suprathreshold dose (as a % of normal dose), and the remaining studies administered the subjects' usual morning dose.
The clinical characteristics of the patient groups included in the analysis are presented in table 1. At baseline assessment the patients who would go on to receive STN and GPi DBS were equivalent in terms of motor UPDRS (part III), disease duration, and length of maximum follow-up time, but the GPi subjects included more females and were slightly younger at onset, although distributions overlapped.
Composite score calculation. UPDRS scores were collated for the cardinal signs of tremor (items 20 and 21, with a maximum score of 28), rigidity (item 22, with a maximum score of 20), and bradykinesia (items 23, 24, 25, and 26, with a maximum score of 32) as well as for the PIGD signs of gait (item 29, with a maximum score of 4) and postural stability (item 30, with a maximum score of 4). Arising from a chair (item 27) and posture (item 28) were not consistently reported so these items could not be included in the PIGD composite measure. Initial meta-analyses showed that scores of tremor, rigidity, and bradykinesia had similar outcomes and thus were normalized so each had equal weight in a composite "cardinal" measure with a maximum possible score of 4. Gait and postural stability scores were also combined and normalized to have a maximum score of 4 in a single measure "PIGD." Not all studies presented the values of individual UPDRS items. For the 2 studies that reported only a composite "axial score" 25, 26 that included rise from a chair and postural alignment as well as items 29 and 30, the axial score was normalized to a maximum of 4 and was included as a measure of PIGD. As can be seen in table 1, there was no systematic difference before surgery in PIGD or total UPDRS between STN and GPi groups.
Medication and stimulation changes over time.
The modifications to levodopa medication dose and stimulation frequency across time are presented in table 2. On average, by the final follow-up the levodopa equivalent medication dosage was approximately half its level before surgery in the STN group (48.1%), whereas the mean dose for the GPi group had not changed significantly, although it was quite variable among studies. All studies reported a levodopa-induced dyskinesia score either from the UPDRS IV questionnaire or from patient diaries. The percentage changes in dyskinesias were measured by comparing the postoperative condition with medication ON and stimulation ON to the preoperative state with medication. For all studies there was a significant decrease in the amount of time spent ON with dyskinesia after surgery, and this was maintained across time. The studies with the most marked reduction in dyskinesias were for STN DBS. As can be seen in table 2, stimulation frequencies were in the range of 138 to 181 Hz with no systematic difference between STN and GPi sites. It was generally reported that stimulation settings of the DBS did not change significantly over time.
Statistical analysis. To investigate changes in motor function
with DBS, a weighted meta-regression was performed for PIGD and cardinal measures. For each study, a standardized change score was calculated for each follow-up assessment, which was the difference between the composite score at the assessment time and the presurgery score, divided by the average SD of each score. Two sets of scores were compared: 1) postoperative OFF medication and ON DBS function compared to preoperative OFF medication function and 2) postoperative ON medication and ON DBS function compared to preoperative ON medication function.
Despite low heterogeneity (with I 2 values ranging from 0 to 0.4), a random effects model was used to provide greater rigor to the analysis, particularly given the lack of randomization. 28 Uncontrollable sources of heterogeneity between studies include differences in surgical techniques, skill of the surgeons, the length of time between initial assessment and surgery (ranging from a couple of days to 6 weeks), as well as environmental and lifestyle differences in the populations. Time since surgery (years) was a continuous covariate in the regression analysis. Levodopa reduction was not used as a covariate because the values provided by the articles were mean values, so as the variability across studies was less than variability within studies the utility of this measure is limited. 29 A random effects meta-analysis was also performed to determine the effect of medication on the PIGD and cardinal scores by comparing standardized changes in the presurgery OFF and ON states within studies. Confidence intervals and the effect size were calculated for each study. Custom written syntax in Predictive Analytics SoftWare (PASW) version 18 was used to perform all statistical analyzes. 30 RESULTS Summary. DBS surgery initially improved PIGD scores. However, as time progressed, PIGD significantly worsened. In contrast, the initial improvement in cardinal scores with DBS was maintained over 5 years. The standardized change scores of at each assessment time for each of the studies are presented in the figure.
Posture and gait changes. The regressions for PIGD in the OFF medication state were similar for STN and GPi groups ( 2 ϭ 0.19, p ϭ 0.66). DBS initially improved PIGD when compared to the OFF medication state before surgery ( figure, A) . This initial improvement is revealed by a constant in the regression which is less than zero (95% CI Ϫ1.869 to Ϫ1.015, p Ͻ 0.001). However, DBS was associated with worsening of PIGD symptoms as the years progressed, as indicated by a positive slope of the regression with follow-up time (95% CI 0.017 to 0.296, p ϭ 0.029). Extrapolating from the regression slope, patients would be predicted to have worse PIGD with DBS than their presurgery medicated OFF state by 9 years postsurgery. Presurgery, PIGD ratings were improved ON medication compared to OFF medication, with a pooled effect of Ϫ1.67 (95% CI Ϫ2.02 to Ϫ1.32). Postsurgery, there was an initial improvement in PIGD with DBS over and above the effects of medication (figure, B) , with the intercepts of the regression different from zero for both STN (95% CI Ϫ0.747 to Ϫ0.090, p ϭ 0.016) and GPi (95% CI Ϫ1.40 to Ϫ0.267, p ϭ 0.029). This was a larger effect in GPi compared to STN ( 2 ϭ 12.1, p ϭ 0.001). As time progressed, the STN group had worsening of PIGD (95% CI 0.105 to 0.318, p ϭ 0.001) and by 2 years PIGD was on average worse than the presurgery medicated ON state. In contrast, the GPi group did not have deterioration in PIGD ON medication, cardinal symptoms with DBS initially improved over and above medication alone presurgery for both STN and GPi sites (95% CI Ϫ1.302 to Ϫ0.519, p Ͻ 0.001) ( figure, D) . The gradient of the regression slope over time was not different from zero for both the STN ( p ϭ 0.085) and GPi groups ( p ϭ 0.553).
DISCUSSION
This meta-analysis of the long-term effects of DBS on PD motor symptoms shows that despite initial improvement in posture and gait, PIGD scores declined after surgery. In contrast, the improvement in cardinal signs after DBS were maintained. GPi stimulation combined with medications preserved balance and gait function better than STN stimulation combined with medications.
Effect of DBS OFF medication.
The effect of DBS on the progression of the symptoms of PD is revealed by motor function in the OFF medication state before and after surgery. After an initial improvement in both cardinal and PIGD symptoms, the improve-ment in cardinal symptoms is maintained while PIGD symptoms worsen. One explanation might be that the stimulation settings are programmed to alleviate the cardinal symptoms, but not the PIGD symptoms. However, a review of the long-term settings showed that the voltage, pulse width, and frequency of stimulation were not modified significantly beyond the first 6 months in the studies included in the meta-analysis. So, with the stimulation settings stable over time, the decline in PIGD function without a decline in cardinal symptoms implies a different mode of action of DBS on axial motor control.
The initial benefit of DBS surgery observed in the PIGD symptoms may be a direct result of improvements in rigidity and bradykinesia that were constraining posture and gait. Meanwhile, other sensorimotor circuits involved in balance and gait control that are not responsive to DBS continue to decline as the disease progresses. Laboratory studies quantifying the effects of DBS on particular systems underlying balance control supports this theory as they suggest that DBS can improve some balance subsystems but impair, or not improve, others. For example, DBS improves rigidity affecting postural control. Reducing excessive postural muscle tone improves static postural alignment. 31 Improvement of bradykinetic postural movements with DBS produces faster and larger voluntary movements of the body center of mass. 10 However, other systems underlying the control of balance are worse after surgery, such as anticipatory postural adjustments prior to rising onto toes, 32 and recent work shows no improvement in automatic, feet in place, postural responses. 33 Thus, balance is comprised of many physiologic functions, some of which are improved and some potentially worsened by DBS.
Similarly, DBS improves some gait subsystems but not others. Stride length and gait speed, both related to bradykinesia, increase during STN DBS. [34] [35] [36] [37] [38] [39] Improved postural alignment during gait, related to reduced rigidity, also is seen. 35 In contrast, the timing characteristics of gait, such as cadence 36, 37 and variability in stride and swing time, 38 may not improve with DBS. More challenging locomotor tasks such as changing direction and dual tasking, which are often associated with falls, 39 have not been evaluated. Quantitative laboratory studies comparing the effects of DBS in the STN and GPi on spatial and temporal characteristics of gait are also lacking.
The notion that axial and distal PD motor symptoms are controlled by different physiologic mechanisms is supported by the observation of different latencies to changes in particular PD signs after turning DBS on. 40 Tremor is affected almost instantly, followed by rigidity and bradykinesia, whereas maximal locomotion and balance changes are delayed for a few hours. 41
Effect of DBS ON medication.
Investigating the effects of DBS while patients are taking levodopa provides insight into the interaction between levodopa and DBS in patients' clinically functional state. The improvement in PIGD scores with GPi stimulation combined with levodopa is maintained for up to 5 years. In contrast, the improvement of PIGD scores with STN stimulation combined with levodopa declines over time. What are the possible reasons for this difference between the effects of DBS in GPi and STN over time? One possibility is that the difference in doses of antiparkinsonian medications associated with STN and GPi stimulation is responsible. Medication doses did not change significantly between presurgery and postsurgery for subjects receiving GPi DBS, whereas the presurgery levodopa dose was reduced by half in the subjects receiving STN DBS. The higher relative levels of dopaminergic medication taken by patients after GPi may prevent progression of PIGD by improving aspects of balance or gait not adequately treated with DBS. Indeed, across the studies the percentage reduction in the levodopa equivalent dose was correlated with worsening of the ON medication PIGD change score (R ϭ Ϫ0.54, p ϭ 0.003). However, within the STN group this correlation did not reach statistical significance. This could be because levodopa-induced dyskinesias are confounding the effects in this group because implantation at STN tends to be favored for patients who have the most severe problems with levodopainduced dyskinesias. This tendency is reflected in the analyzed studies with the STN populations showing a greater reduction in medication and associated dyskinesias postsurgery (table 2) . Therefore, reducing the medications in the STN group may be pulling the PIGD score in 2 opposing directions: 1) reducing dyskinesias, which serves to improve PIGD; and 2) reducing the function of dopaminergic circuitry, which serves to worsen PIGD.
Another possibility to explain the differences in GPi and STN stimulation over time is that the GPi site may have greater influence on PIGD in the medicated state by its more direct connections to the motor and premotor cortex via the thalamus or because of activation of axons of passage in dorsolateral GPi to the midbrain. 42 Increased understanding of the mechanism of DBS and the pathophysiology of the basal ganglia are needed to resolve this issue. Recent studies examining stimulation optimization have shown improved gait and balance by stimulating at lower frequencies (ϳ60 Hz) in STN, 43 or stimulating lower contacts (inside SNr). 44 The stimulation fre-quencies were similar among the articles in the current analysis (table 1) ; however, subtle differences in site-specific responses to the stimulation settings may have some bearing on the response.
Cardinal signs, compared to the treated state before surgery, are improved with DBS alone and combined with medication therapy out to 5 years after surgery. DBS is generally considered to be a symptomatic treatment that does not modify the disease progression. However, these results are consistent with a disease-modifying effect.
Possible disease-modifying effects. Motor function examined with the stimulator turned off may better reveal the natural state of the disease and whether DBS has modified progression of motor symptoms. A handful of the long-term studies report these effects. Cardinal signs of tremor and rigidity were not significantly different between the OFF DBS/OFF medication state 4 to 5 years postsurgery and the OFF medication presurgery [21] [22] [23] [24] but bradykinesia had worsened somewhat. [21] [22] [23] In contrast, PIGD scores OFF DBS and OFF medication had deteriorated significantly 4 to 5 years after DBS, compared to the pre-DBS OFF medication scores. [21] [22] [23] Two of these studies tested patients with the stimulator turned off for 10 -12 hours. 21, 22 Given this long duration, it is unlikely that the cardinal symptoms were affected by lingering benefit from the stimulation. 41 Unfortunately, there are currently no longitudinal studies of patients with PD who are candidates for DBS but who did not get DBS surgery to compare the natural history of symptom progression at this stage of the disease.
DBS may slow functional progression because patients are more active and exercising more after surgery. In rodent models of PD, exercise has been shown to have neuroprotective benefits, preventing dopaminergic neuronal loss in regions of the basal ganglia. [45] [46] [47] There also is evidence that exercise may improve function without preserving dopaminergic neurons 48, 49 presumably through compensatory mechanisms. In human subjects with PD, treadmill training has produced improvements in gait, quality of life, and levodopa efficacy. [50] [51] [52] So although the precise mechanisms remain to be determined, there is growing evidence that physical activity can curb the rate of motor function decline.
Limitations. Assertions about the relative benefits of GPi over STN surgery for PIGD must be tempered by the fact that fewer long-term studies of GPi stimulation exist and there are no randomized control subjects without surgery. This meta-regression suggests the possibility that GPi may be a superior site for DBS to maintain posture and balance associated with PD and stresses the need for more studies of DBS in the GPi to determine whether this is unequivocally the case.
A problem with studies stretching over many years is that the data belong to subjects who survived for the duration of the study, and neglect those who died along the way. All studies had dropouts; overall 11% of the original recruits died before the final assessment for various reasons. CONCLUSIONS This meta-analysis of the longterm efficacy of DBS has shown that the benefits to posture and gait function are not maintained to the same extent as are the benefits to the cardinal symptoms of PD. Further, the results suggest that GPi may be a superior site to STN for sustaining gait and posture function in combination with levodopa. Long-term follow-up of the randomized controlled trial comparing DBS in GPi and STN will be important. 3 It is hoped that this analysis will foster renewed interest in the underlying neural mechanisms for gait and balance in PD and the effects of levodopa and DBS on these mechanisms.
